Aligos Therapeutics News

Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)

TipRanksMay 17 18:27

Aligos Therapeutics Announces Chief Medical Officer Resignation

TipRanksMay 16 05:12

Aligos Therapeutics Reports Q1 Results

Seeking AlphaMay 8 22:42

Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

TipRanksMay 8 19:10

Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses o

BenzingaMay 8 05:07

Aligos Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 04:52 · Announcements

Aligos Therapeutics 1Q Loss/Shr 22c >ALGS

Aligos Therapeutics 1Q Loss/Shr 22c >ALGS

Dow JonesMay 8 04:05

Press Release: Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "A

Dow JonesMay 8 04:05

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet

GlobeNewswireMay 1 04:05

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 From the ALG-097558 Phase 1 Study

Globe NewswireApr 26 04:05

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet

GlobeNewswireApr 25 20:00

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic

GlobeNewswireApr 9 20:00

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

BenzingaApr 3 20:18

Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH

Seeking AlphaApr 2 20:59

Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19

Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19

BenzingaApr 1 23:31

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 From ALG-055009 and ALG-000184 Phase 1 Studies

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic

GlobeNewswireMar 27 20:00

Aligos Therapeutics Announces Initiation Of Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

Aligos Therapeutics Announces Initiation Of Phase 2a HERALD Study Of ALG-055009 In MASH Subjects

BenzingaMar 18 20:01

12 Health Care Stocks Moving In Friday's After-Market Session

GainersCue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came ou

BenzingaMar 16 05:33

Maintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics' Clinical Pipeline

TipRanksMar 15 13:25

Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences

TipRanksMar 14 14:01